Please see below for a list of search results.
We were asked to provide original documentation submitted as part of King's Health Partners Cancer Biobank's application for an HTA licence.
The HTA was asked to provide information on whether the company ‘Celixir’ had an HTA licence from 2010-13, for importing blood from patients at the Morriston Hospital and deriving mesenchymal stromal cells for research purposes.
HTA was asked to provide information on its workforce expenses between April and May 2019.
The HTA was asked to provide documentation - including letters, emails, reports, and meeting minutes - related to concens about the Wellcome Sanger Institute's compliance with the Human Tissue Act in 2019.
The HTA was asked to provide information on the Serious Adverse Events and Reactions in the organ donation and transplantation sector.
The HTA was asked to provide correspondence relating to the discussion of a proposed development of a human taphonomy facility in the UK
We were asked to provide information on the complaints against the Wellcome Sanger Institute regarding the handling and storage of human tissue. We were also asked to provide reports on the compliance of the establishment and our communications with them.
We were asked to provide information on the HTA Reportable Incidents for 2018.
We were asked to provide a list of all HTA Reportable lncidents that took place in 2018.